fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Takeda provides update on Exkivity (mobocertinib) for epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive NSCLC

Written by | 9 Oct 2023

Takeda announced that, following discussions with the FDA, it will be working with the FDA towards a voluntary withdrawal of Exkivity (mobocertinib) in the U.S. for adult patients… read more.

Nivolumab appears to benefit patients with stage III lung cancer

Written by | 12 Aug 2023

Among patients with resectable stage IIIA or IIIB NSCLC (non–small-cell lung cancer), those treated with neoadjuvant nivolumab plus chemotherapy have achieved a higher level of complete response and… read more.

Survival benefit from frontline immunotherapy in progression-free non–small cell lung cancer peaks at 2 years

Written by | 13 Jun 2023

For patients who are progression-free after two years of frontline immunotherapy for advanced non–small cell lung cancer (NSCLC), there does not appear to be a survival benefit in… read more.

NICE UK recommends Keytruda with carboplatin and paclitaxel for metastatic squamous non-small-cell lung cancer – Merck Inc

Written by | 27 Feb 2022

NICE (UK): Keytruda (pembrolizumab), from Merck Inc. with carboplatin and paclitaxel is recommended as an option for untreated metastatic squamous non-small-cell lung cancer (NSCLC) in adults, only if… read more.

Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Written by | 8 Feb 2022

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS)… read more.

Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic NSCLC – Roche

Written by | 19 May 2021

Roche has announced that the European Commission has approved Tecentriq (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.